<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217565</url>
  </required_header>
  <id_info>
    <org_study_id>1986-014</org_study_id>
    <secondary_id>2017-000953-38</secondary_id>
    <secondary_id>MK-1986-014</secondary_id>
    <nct_id>NCT03217565</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)</brief_title>
  <official_title>A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to describe the single-dose, and multiple dose&#xD;
      pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral&#xD;
      suspension of tedizolid phosphate, when administered to pediatric participants, full-term&#xD;
      neonates, and preterm neonates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-last of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to time of last quantifiable drug concentration (AUC0-last) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity (AUC0-inf) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Maximum concentration (Cmax) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Time to reach Cmax (Tmax) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of tedizolid phosphate</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Apparent terminal half-life (t1/2) of plasma tedizolid phosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to time of last quantifiable drug concentration of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Maximum concentration of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Time to reach Cmax of plasma tedizolid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of tedizolid</measure>
    <time_frame>IV Treatment: after the end of infusion, 1.5, 3, 6, 12, 24 hours after the start of infusion; Oral Suspension Treatment: 1, 3, 5, 8, 12, and 24 hours postdose</time_frame>
    <description>Apparent terminal half-life of plasma tedizolid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to Day 21</time_frame>
    <description>Number of participants with one or more adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of participants who discontinued from study due to an AE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Gram-Positive Infections</condition>
  <arm_group>
    <arm_group_label>IV Tedizolid Phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered intravenously (IV). For body weight &lt;10 kg: 3 mg/kg; for body weight 10 to &lt;30 kg: 2.5 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Suspension Tedizolid Phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of tedizolid phosphate administered as an oral suspension. For body weight &lt;10 kg: 3 mg/kg; for body weight 10 to &lt;30 kg: 2.5 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Tedizolid Phosphate</intervention_name>
    <description>A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.</description>
    <arm_group_label>IV Tedizolid Phosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Suspension Tedizolid Phosphate</intervention_name>
    <description>A single dose of tedizolid phosphate administered as an oral suspension.</description>
    <arm_group_label>Oral Suspension Tedizolid Phosphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is receiving prophylaxis for or has a confirmed or suspected infection with&#xD;
             gram-positive bacteria and receiving concurrent antibiotic treatment with gram&#xD;
             -positive antibacterial activity.&#xD;
&#xD;
          -  Is at least 1 kg in weight.&#xD;
&#xD;
          -  Is in stable condition as determined from medical history, physical examination,&#xD;
             electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.&#xD;
&#xD;
          -  Has no clinically significant ECG abnormalities.&#xD;
&#xD;
          -  Has sufficient vascular access to receive trial drug, and allow for required blood&#xD;
             draws.&#xD;
&#xD;
          -  Is able to receive medication by mouth, for those dosed with oral suspension; dose&#xD;
             administration via feeding tube is acceptable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of seizures, other than febrile seizures, clinically significant cardiac&#xD;
             arrhythmia or condition, moderate or severe renal impairment, or any physical&#xD;
             condition that could interfere with the interpretation of the study results, as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          -  Has used rifampin within 14 days prior to dosing.&#xD;
&#xD;
          -  Has used or will be using proton pump inhibitors, H2 blockers, or antacids (for&#xD;
             participants in Part B, i.e, oral suspension dose) at any time from 24 hours prior to&#xD;
             dosing through 24 hours after dosing..&#xD;
&#xD;
          -  Has a recent (3-month) history or current infection with viral hepatitis or other&#xD;
             significant hepatic disease.&#xD;
&#xD;
          -  Has a history of drug allergy or hypersensitivity to oxazolidinones.&#xD;
&#xD;
          -  Has had significant blood loss.&#xD;
&#xD;
          -  Need for oral administration of topotecan, rosuvastatin, irinotecan, or methotrexate&#xD;
             during administration of oral study drug.&#xD;
&#xD;
          -  Used monoamine oxidase inhibitors (MAOIs) or serotonergic agents including tricyclic&#xD;
             antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin&#xD;
             5-hydroxytryptamine receptor agonists (triptans), meperidine, or buspirone within 14&#xD;
             days prior to study, or planned use while on study.&#xD;
&#xD;
          -  Has received another investigational product within the 30 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital ( Site 1012)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 1001)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-509-4791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital ( Site 1021)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-939-7424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 1022)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-6285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center. ( Site 1004)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis Children's Hospital ( Site 1020)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital ( Site 1000)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical Center - 1- Sevlievo EOOD ( Site 2207)</name>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Ivan Rilski EOOD ( Site 2201)</name>
      <address>
        <city>Kozloduy</city>
        <state>Vratsa</state>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Deva Maria ( Site 2208)</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359884386907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT City Clinic Sv. Georgi EOOD ( Site 2202)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski EAD ( Site 2211)</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358887591823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Rousse-Neonatology ( Site 2213)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887096090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Ruse ( Site 2204)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD ( Site 2209)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Ival Seliminski ( Site 2212)</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359898309092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Vicente Fundacion ( Site 1103)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 1106)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5753369999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital Infantil Universitario de San Jose ( Site 1107)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573108059791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 1102)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF ( Site 1604)</name>
      <address>
        <city>Loerenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4741469314</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssjukehus ( Site 1602)</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+475975720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssykehus, Helse Stavanger ( Site 1601)</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+47515159940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital. ( Site 1600)</name>
      <address>
        <city>Trondheim</city>
        <state>Sor-Trondelag</state>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4772251241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust ( Site 1700)</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441223216555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens NHS Foundation Trust Hospital ( Site 1703)</name>
      <address>
        <city>Liverpool</city>
        <state>Lancashire</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary ( Site 1702)</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441912821527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust ( Site 1704)</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441512525570</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tedizolid</mesh_term>
    <mesh_term>Tedizolid phosphate</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

